By the Top Tier Newswire AI Desk · August 26, 2026 at 10:50 AM ET · reviewed against 1 wire stories
ERASCA INC (ERAS) is up +9.01% in the latest session. Our newswire has captured 1 story on ERAS across 1 source in the last 36 hours, with AI sentiment reading mixed (avg 50/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
ERAS stock rose 9.01% to $19.36 in morning trade driven by a combination of renewed analyst optimism and a regulatory development in its pipeline. The stock opened with a modest gap down but quickly reversed course, hitting a session high of $19.50 before settling near that level. The move follows a recent Fast Track Designation from the FDA for one of its key candidates and a series of upgraded price targets from major analysts.
What Happened
Erasca Inc. announced that the U.S. Food and Drug Administration has granted Fast Track Designation to ERAS-0015 for the treatment of metastatic pancreatic adenocarcinoma. This regulatory milestone is typically associated with expedited review and increased visibility for drug developers. In response, multiple analysts have raised their price targets for the stock. B of A Securities raised its target to $20, Guggenheim to $21, and HC Wainwright & Co. to $22, all maintaining Buy or Neutral ratings. These upgrades suggest growing confidence in the company’s pipeline and potential for near-term progress.
The stock has also drawn attention from long-term shareholders, as the Grabar Law Office issued a notice regarding potential claims for investors in Erasca and other companies. While the legal implications remain unclear, the notice has generated additional interest in the stock.
What The Data Shows
The stock opened at $17.56, a -1.1% gap from the prior close, but quickly reversed course, reaching a high of $19.50. The session low was $17.24, and as of the latest data, the stock traded at $19.07. Volume was 1.4 million shares, or 0.2 times the 3-month daily average. The stock has a market capitalization of $6.2 billion and is currently unprofitable, with a trailing twelve-month EPS of -0.97. It has a beta of 0.65, indicating lower volatility than the broader market. The stock has traded between $1.33 and $24.28 over the past 52 weeks and has printed 9 fresh 52-week highs and 5 fresh 52-week lows on August 26, 2026.
What To Watch
The company is set to report its next earnings release, which will provide further insight into its operational progress. Investors should also monitor the breadth of analyst coverage and any additional regulatory developments related to ERAS-0015.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
ERAS · Aug 26 session (5-min) · +8.11% vs prior close · updated 8:52 PM ETAI sentiment, last 36h · averaged over 1 story · 50/100 neutral
The headlines behind the move
Story flow · 1 story on the wire, last 36h · hover or tap a dot for the headline
18d agoGlobeNewswireNEUTRAL 50General
Important Notice to Long-Term Shareholders of Erasca, Inc. (NASDAQ: ERAS); Insulet Corporation (NASDAQ: PODD); New Era Energy & Digital, Inc. (NASDAQ: NUAI) (formerly known as New Era Helium (NASDAQ: NEHC)); and Power Solutions International, Inc. (NASDAQ: PSIX): Grabar Law Office is Investigating Claims on Your Behalf
Erasca, Inc. (NASDAQ: ERAS); Insulet Corp. (NASDAQ: PODD); New Era Energy & Digital, Inc. (NASDAQ: NUAI); and Power Solutions Int
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →